Copenhagen, Denmark - 8 April, 2011 - Today Topotarget A/S (NASDAQ OMX:
TOPO.CO) announced the establishment of the Global Oncology Advisory Board.

Topotarget presents the formation of its Global Oncology Advisory Board (GOAB).
Professor Jean-Louis Misset is chairing the board. Professor Misset has a
strong oncology background as an advisor in the field of drug development. He
has been instrumental in the development of several important oncology drugs
from companies such as Aventis, Roche and Eli Lilly. Furthermore he has
published more than 200 publications in internationally well-known referenced
journals.


We are confident this group of key opinion leaders will support our efforts in
developing our lead compound belinostat. The members of the board are:


-- Professor Jean-Louis Misset
-- Professor of Oncology at the University and at the St. Louis Hospital
Oncology Division in Paris, France
-- Dr. Matti Aapro
-- Dean of the Multidisciplinary Oncology Institute, Genolier, Switzerland
-- Professor James Cassidy
-- Professor of Oncology and Head of Academic Unit, University of Glasgow,
Scotland
-- Assistant Professor Alain Catalin Mita
-- Assistant Professor of Medicine at the University of Texas Health
Science Center San Antonio, Texas, US
-- Professor Hans-Joachim Schmoll
-- Professor of Internal Medicine and Director of the Department of
Haematology and Oncology at the Martin Luther University,
Halle-Wittenberg, Germany
-- Dr. Daniel D. Von Hoff
-- Physician in Chief, Senior Investigator and Director of Clinical
Translational Research Division at TGen (Translational Genomics Research
Institute) in Phoenix, Arizona, US

In connection with the formation of the GOAB additional indication-specific
advisory boards (ISAB) within CUP (cancer of unknown primary), NSCLC (non-small
cell lung cancer), bladder cancer, ovarian cancer, and CRC (colorectal cancer)
are formed. These ISABs will improve the understanding of the pre-clinical and
clinical work of belinostat.

Francois Martelet, CEO says: “We are very pleased to work with this group of
distinguished oncologists representing several indications within oncology.
During 2010 we have held two meetings and have discussed several potential
development strategies for belinostat”. He continues: “During 2011 we plan to
hold additional meetings with our global advisors and we believe that their
acceptance to join this advisory board is an endorsement of the potential of
belinostat”.


Today's news does not change Topotarget's full-year financial guidance.



Topotarget A/S


For further information, please contact:

Francois Martelet, CEO: Direct: +45 39 17 83 41; Mobile: +45 51
32 83 41

Axel Mescheder, CDMO: Direct: +45 39 17 83 14; Mobile: +45 51 55
71 66

Annette Lykke, IR Direct: +45 39 17 83 44; Mobile: +45
23 28 98 14



Background information


About belinostat

Belinostat is a promising small molecule HDAC inhibitor being investigated for
its role in the treatment of a wide range of solid tumors and hematologic
malignancies either as a single agent, or in combination with other active
anti-cancer agents, including carboplatin, paclitaxel, doxorubicin, idarubicin,
cis-retinoic acid, azacytidine, 5-FU, etoposide and Velcade® (bortezomib) for
injection. HDAC inhibitors represent a new mechanistic class of anti-cancer
therapeutics that target HDAC enzymes, and have been shown to: Arrest growth of
cancer cells (including drug-resistant subtypes); induce apoptosis, or
programmed cell death; promote differentiation; inhibit angiogenesis; and
sensitize cancer cells to overcome drug resistance when used in combination
with other anti-cancer agents.


Intravenous belinostat is in pivotal trial in peripheral T-cell lymphoma (PTCL)
and is currently being evaluated in multiple clinical trials as a potential
treatment for cancer of unknown primary (CUP), ovarian cancer, small cell lung
cancer, thymoma, liver, soft tissue sarcoma, lymphoma, AML, and Myelodysplastic
Syndrome (MDS), either alone or in combination with other anti-cancer
therapies. Continuous intravenous administration (CIV) is being evaluated in
clinical trials in solid tumours as well as in AML. Topotarget has a Clinical
Trial Agreement (CTA) with the NCI to clinical studies on belinostat in order
to better understand its anti-tumor activity.


About Topotarget

Topotarget (NASDAQ OMX: TOPO.CO) is a Scandinavian-based international biotech
company headquartered in Denmark, dedicated to improve cancer therapies. In
collaboration with Spectrum Pharmaceuticals, Inc. Topotarget currently focuses
on the development in pivotal studies of its lead drug candidate, belinostat,
which has demonstrated a clear anti-neoplastic effect in both hematological
malignancies and solid tumors. Belinostat can be used in combination with full
doses of chemotherapy, and is currently in a pivotal trial within PTCL
(peripheral T-cell lymphoma) and phase II in cancer of unknown primary site
(CUP). Topotarget's cancer drug targets are HDAC, NAD+, and topoisomerase II.
Totect® is a product on the market developed from Topotarget's drug discovery
technology. Totect® is marketed by the company's own sales specialists in the
US. The European rights to Savene® were divested in March 2010 as a consequence
of the focus to develop and commercialize belinostat. For more information,
please refer to www.topotarget.com.


Topotarget Safe Harbour Statement

This announcement may contain forward-looking statements, including statements
about our expectations of the progression of our preclinical and clinical
pipeline including the timing for commencement and completion of clinical
trials and with respect to cash burn guidance. Such statements are based on
management's current expectations and are subject to a number of risks and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. Topotarget cautions investors that
there can be no assurance that actual results or business conditions will not
differ materially from those projected or suggested in such forward-looking
statements as a result of various factors, including, but not limited to, the
following: The risk that any one or more of the drug development programs of
Topotarget will not proceed as planned for technical, scientific or commercial
reasons or due to patient enrollment issues or based on new information from
non-clinical or clinical studies or from other sources; the success of
competing products and technologies; technological uncertainty and product
development risks; uncertainty of additional funding; Topotarget's history of
incurring losses and the uncertainty of achieving profitability; Topotarget's
stage of development as a biopharmaceutical company; government regulation;
patent infringement claims against Topotarget's products, processes and
technologies; the ability to protect Topotarget's patents and proprietary
rights; uncertainties relating to commercialization rights; and product
liability exposure; We disclaim any intention or obligation to update or revise
any forward-looking statements, whether as a result of new information, future
events, or otherwise, unless required by law.

Announcement No 08-11 Establisment of Global Oncology Advisory Board.pdf